Literature DB >> 10971291

The role of the activated form of matrix metalloproteinase-2 in urothelial cancer.

K Kanda1, M Takahashi, Y Murakami, H Kanayama, S Kagawa.   

Abstract

OBJECTIVE: To investigate the expression of matrix metalloproteinase-2 (MMP-2, reportedly associated with cancer cell invasion and metastasis in many human cancers) in urothelial tumours and thus define its role in this disease. Materials and methods The expression of both the activated form of MMP-2 and total MMP-2 (activated + latent form) was measured using gelatine zymography in tissue obtained surgically from 61 patients with urothelial cancer. The correlation between the level of the activated form of MMP-2 and clinical and histological variables was assessed.
RESULTS: The expression of activated and total MMP-2 were significantly higher in invasive tumour tissue and both levels were correlated with histological grade. In particular, the level of activated MMP-2 was more closely correlated than that of total MMP-2 in invasive tumour tissue. Moreover, high levels of activated MMP-2 were strongly associated with shorter disease-specific survival (P = 0.0016).
CONCLUSION: These findings suggest that activated MMP-2 plays a significant role in invasion of urothelial cancer and that the level of activated MMP-2 expression is a useful prognostic indicator.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971291     DOI: 10.1046/j.1464-410x.2000.00734.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  2 in total

1.  Sensitive surface enhanced Raman scattering multiplexed detection of matrix metalloproteinase 2 and 7 cancer markers.

Authors:  Tianxun Gong; Kien Voon Kong; Douglas Goh; Malini Olivo; Ken-Tye Yong
Journal:  Biomed Opt Express       Date:  2015-05-12       Impact factor: 3.732

2.  Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma.

Authors:  M J Wallard; C J Pennington; A Veerakumarasivam; G Burtt; I G Mills; A Warren; H Y Leung; G Murphy; D R Edwards; D E Neal; J D Kelly
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.